Vargo Janet 4
4 · ALPHA HEALTHCARE ACQUISITION CORP III · Filed Jul 18, 2023
Insider Transaction Report
Form 4
Vargo Janet
VP Clinical Services
Transactions
- Award
Stock Options (right to buy)
2023-07-14+12,309→ 12,309 totalExercise: $2.60Exp: 2032-12-15→ Common Stock (12,309 underlying) - Award
Stock Options (right to buy)
2023-07-14+119,098→ 119,098 totalExercise: $2.11Exp: 2031-09-23→ Common Stock (119,098 underlying) - Award
Common Stock
2023-07-14+27,030→ 27,030 total - Award
Stock Options (right to buy)
2023-07-14+1,045→ 1,045 totalExercise: $1.79Exp: 2027-06-20→ Common Stock (1,045 underlying) - Award
Stock Options (right to buy)
2023-07-14+16,629→ 16,629 totalExercise: $2.27Exp: 2029-07-19→ Common Stock (16,629 underlying)
Footnotes (5)
- [F1]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation.
- [F2]Options are fully vested and exercisable.
- [F3]Options to purchase 119,098 shares of Common Stock granted on September 23, 2021, which vest as follows: (i) 25% vested on September 23, 2022 and the remaining 75% will vest in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F4]Options to purchase 12,309 shares of Common Stock granted on December 15, 2022, which vest as follows: (i) 25% will vest on December 15, 2023 and the remaining 75% will vest in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F5]As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.